These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 28000552)

  • 1. Studies of KP46 and KP1019 and the Hydrolysis Product of KP1019 in Lipiodol Emulsions: Preparation and Initial Characterizations as Potential Theragnostic Agents.
    Pashkunova-Martic I; Losantos BC; Kandler N; Keppler B
    Curr Drug Deliv; 2018; 15(1):134-142. PubMed ID: 28000552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism.
    Bijelic A; Theiner S; Keppler BK; Rompel A
    J Med Chem; 2016 Jun; 59(12):5894-903. PubMed ID: 27196130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly(lactic acid) nanoparticles of the lead anticancer ruthenium compound KP1019 and its surfactant-mediated activation.
    Fischer B; Heffeter P; Kryeziu K; Gille L; Meier SM; Berger W; Kowol CR; Keppler BK
    Dalton Trans; 2014 Jan; 43(3):1096-104. PubMed ID: 24165902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and reactivity of the aquation product of the antitumor complex trans-[Ru(III)Cl4(indazole)2]-.
    Cebrián-Losantos B; Reisner E; Kowol CR; Roller A; Shova S; Arion VB; Keppler BK
    Inorg Chem; 2008 Jul; 47(14):6513-23. PubMed ID: 18553904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer ruthenium(III) complex KP1019 interferes with ATP-dependent Ca2+ translocation by sarco-endoplasmic reticulum Ca2+-ATPase (SERCA).
    Sadafi FZ; Massai L; Bartolommei G; Moncelli MR; Messori L; Tadini-Buoninsegni F
    ChemMedChem; 2014 Aug; 9(8):1660-4. PubMed ID: 24920093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of the anticancer gallium(III) complexes of 8-hydroxyquinoline and maltol with human serum proteins.
    Enyedy ÉA; Dömötör O; Bali K; Hetényi A; Tuccinardi T; Keppler BK
    J Biol Inorg Chem; 2015 Jan; 20(1):77-88. PubMed ID: 25398250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019.
    Bartel C; Egger AE; Jakupec MA; Heffeter P; Galanski MS; Berger W; Keppler BK
    J Biol Inorg Chem; 2011 Dec; 16(8):1205-15. PubMed ID: 21706338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osmium(III) analogues of KP1019: electrochemical and chemical synthesis, spectroscopic characterization, X-ray crystallography, hydrolytic stability, and antiproliferative activity.
    Kuhn PS; Büchel GE; Jovanović KK; Filipović L; Radulović S; Rapta P; Arion VB
    Inorg Chem; 2014 Oct; 53(20):11130-9. PubMed ID: 25290960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in developing tris(8-quinolinolato)gallium(iii) as an anticancer drug: critical appraisal and prospects.
    Timerbaev AR
    Metallomics; 2009; 1(3):193-8. PubMed ID: 21305117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins.
    Polec-Pawlak K; Abramski JK; Semenova O; Hartinger CG; Timerbaev AR; Keppler BK; Jarosz M
    Electrophoresis; 2006 Mar; 27(5-6):1128-35. PubMed ID: 16440400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ruthenium anticancer agent KP1019 binds more tightly than NAMI-A to tRNA
    Dwyer BG; Johnson E; Cazares E; McFarlane Holman KL; Kirk SR
    J Inorg Biochem; 2018 May; 182():177-183. PubMed ID: 29501978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CF3 Derivatives of the Anticancer Ru(III) Complexes KP1019, NKP-1339, and Their Imidazole and Pyridine Analogues Show Enhanced Lipophilicity, Albumin Interactions, and Cytotoxicity.
    Chang SW; Lewis AR; Prosser KE; Thompson JR; Gladkikh M; Bally MB; Warren JJ; Walsby CJ
    Inorg Chem; 2016 May; 55(10):4850-63. PubMed ID: 27143338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339.
    Heffeter P; Böck K; Atil B; Reza Hoda MA; Körner W; Bartel C; Jungwirth U; Keppler BK; Micksche M; Berger W; Koellensperger G
    J Biol Inorg Chem; 2010 Jun; 15(5):737-48. PubMed ID: 20221888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mass spectrometry in metallodrug development: a case of mapping transferrin-mediated transformations for a ruthenium(III) anticancer drug.
    Jarosz M; Matczuk M; Pawlak K; Timerbaev AR
    Anal Chim Acta; 2014 Dec; 851():72-7. PubMed ID: 25440667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capillary electrophoretic assay for the stability of tris(8-quinolinolato)gallium(III) in tablet formulations.
    Foteeva LS; Stolyarova NV; Timerbaev AR; Keppler BK
    J Pharm Biomed Anal; 2008 Sep; 48(1):218-22. PubMed ID: 18579328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoformulation improves activity of the (pre)clinical anticancer ruthenium complex KP1019.
    Heffeter P; Riabtseva A; Senkiv Y; Kowol CR; Körner W; Jungwith U; Mitina N; Keppler BK; Konstantinova T; Yanchuk I; Stoika R; Zaichenko A; Berger W
    J Biomed Nanotechnol; 2014 May; 10(5):877-84. PubMed ID: 24734541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies.
    Dömötör O; Hartinger CG; Bytzek AK; Kiss T; Keppler BK; Enyedy EA
    J Biol Inorg Chem; 2013 Jan; 18(1):9-17. PubMed ID: 23076343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR.
    Cetinbas N; Webb MI; Dubland JA; Walsby CJ
    J Biol Inorg Chem; 2010 Feb; 15(2):131-45. PubMed ID: 19707803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. En route to osmium analogues of KP1019: synthesis, structure, spectroscopic properties and antiproliferative activity of trans-[Os(IV)Cl4(Hazole)2].
    Büchel GE; Stepanenko IN; Hejl M; Jakupec MA; Keppler BK; Arion VB
    Inorg Chem; 2011 Aug; 50(16):7690-7. PubMed ID: 21739939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parameters for Stable Water-in-Oil Lipiodol Emulsion for Liver Trans-Arterial Chemo-Eembolization.
    Deschamps F; Moine L; Isoardo T; Tselikas L; Paci A; Mir LM; Huang N; Fattal E; de Baère T
    Cardiovasc Intervent Radiol; 2017 Dec; 40(12):1927-1932. PubMed ID: 28770315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.